We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ADYEN:EURONEXT AMSTERDAMAdyen NV Analysis

Data as of 2026-05-31 - not real-time

€939.30

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Adyen’s shares are trading near their short‑term moving average with the 14‑day RSI hovering around the midpoint, suggesting a balanced momentum outlook. The MACD histogram remains in bullish territory, reinforcing short‑term upside potential while volume trends appear stable. Support sits comfortably above recent lows and resistance is near recent highs, framing a tight trading range. Valuation metrics show a price‑to‑earnings ratio below the industry average, indicating relative value appeal despite a fair‑value estimate that sits lower than the current price. The company delivers exceptionally high operating and profit margins, supported by a strong cash position and minimal debt burden. Analyst sentiment is overwhelmingly positive, with a strong‑buy consensus and market sentiment currently in an extreme greed phase.
The elevated 30‑day volatility and a low beta underscore a market environment that can swing sharply, yet the firm’s diversified global footprint mitigates concentration risk. Regulatory exposure inherent to the payments sector adds a layer of uncertainty, but the firm’s robust risk‑management and compliance capabilities help contain it. Overall, the blend of strong fundamentals, favorable relative valuation, and supportive technical signals points to a compelling, though cautiously managed, investment case.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD histogram indicating upward momentum
  • Price positioned above the short‑term moving average
  • Support level well above recent lows providing downside cushion

Medium Term

1–3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong revenue growth and high operating margins
  • Robust cash reserves with minimal debt
  • Analyst consensus strongly favoring a buy stance

Long Term

> 3 years
Neutral
Model confidence: 8/10

Key Factors

  • Valuation appears balanced relative to intrinsic estimates
  • Continued exposure to regulatory developments in payments
  • Sustainable cash generation supporting strategic investments

Key Metrics & Analysis

Financial Health

Revenue Growth16.90%
Profit Margin44.71%
P/E Ratio27.9
ROE22.33%
ROA5.92%
Debt/Equity4.78
P/B Ratio5.6
Op. Cash Flow€1.0B
Free Cash Flow€534.3M
Industry P/E41.9

Technical Analysis

TrendNeutral
RSI49.5
Support€870.30
Resistance€1,012.40
MA 20€939.99
MA 50€921.59
MA 200€1,216.09
MACDBullish
VolumeStable
Fear & Greed Index94.07

Valuation

Fair Value€786.25
Target Price€1,399.24
Upside/Downside48.97%
GradeFair
TypeBlend

Risk Assessment

Beta0.39
Volatility35.26%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.